Lexicon Pharmaceuticals LXRX Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's accounts receivable?
- Lexicon Pharmaceuticals (LXRX) reported accounts receivable of $11.78M in Q1 2026.
- How has Lexicon Pharmaceuticals's accounts receivable changed year-over-year?
- Lexicon Pharmaceuticals's accounts receivable decreased by 75.2% year-over-year, from $47.45M to $11.78M.
- What is the long-term trend for Lexicon Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), Lexicon Pharmaceuticals's accounts receivable has grown at a 43.3% compound annual growth rate (CAGR), from $395K to $2.38M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.